To the best of our knowledge, this is the first study that defined the study patients as only those with advanced T2DM already on insulin treatment and investigated the effects of DPP-4 inhibitors and SGLT-2 inhibitors on infectious disease risks as compared to metformin effects in these patient populations. The gene discussed is SLC5A2; the disease is infectious disease.